EP1904071A2 - Compositions of antiviral compound - Google Patents

Compositions of antiviral compound

Info

Publication number
EP1904071A2
EP1904071A2 EP06765637A EP06765637A EP1904071A2 EP 1904071 A2 EP1904071 A2 EP 1904071A2 EP 06765637 A EP06765637 A EP 06765637A EP 06765637 A EP06765637 A EP 06765637A EP 1904071 A2 EP1904071 A2 EP 1904071A2
Authority
EP
European Patent Office
Prior art keywords
ribavirin
free flowing
composition
combination
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06765637A
Other languages
German (de)
French (fr)
Inventor
Amod Vishvanath Aurobindo Pharma Limited DHABU
Mohinder Paul Aurobindo Pharma Limited PAKHETRA
Ashish Aurobindo Pharma Limited GOGIA
Sivakumaran Aurobindo Pharma Ltd MEENAKSHISUNDERAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of EP1904071A2 publication Critical patent/EP1904071A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Definitions

  • the present invention relates to composition of an anti-viral compound. More particularly, the present invention relates to compositions comprising free flowing ribavirin.
  • the present invention also relates to a process for the preparation of compositions comprising free flowing ribavirin.
  • Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity and known to be useful in the treatment of hepatitis C as well as various other disease states. Chemically, ribavirin is l-( ⁇ )-D-ribofuranosyl-lH-l,2,4- triazole-3-carboxamide and is commercially available in the US as tablets under the trade name of Copegus®; as capsule and oral solution under the trade name of Rebetol® and as inhalation solution under the trade name of Virazole®. Ribavirin is currently indicated for use as a combination therapy with interferon for Hepatitis C.
  • Ribavirin is administered in large dosages, e.g., a dose as large as 1200 mg per day, together with interferon injections.
  • Ribavirin is a colorless, water-soluble, stable material and is known to have two polymorphic forms. It is very fluffy, non- free flowing powder, which makes it difficult for filling in capsules or as such compressing into tablets. Even after mixing ribavirin with fillers and lubricants, the composition cannot have sufficient flow and density of blend is not suitable for filling into capsules or compressing into tablets.
  • US patent Nos. 5,914,128; 5,916,594; 6,051,252; 6,335,032; and 6,337,090 disclose rapidly dissolving compacted ribavirin composition comprising ribavirin and disintegrant and further disclose the composition having a tap density of at least about 0.6 g/mL.
  • Dry compaction utilizes high pressure to form a ribbon of ribavirin that is subsequently reduced to a free flowing powder by milling.
  • the undesirable side effects of manufacturing ribavirin by dry compaction include creation of excessive dust, a potential health hazard, as well as the risk that high pressure, which can produce high heat, may change the polymorphic forms of ribavirin, which are unacceptable for obtaining health registration.
  • ribavirin is marketed in Canada as capsules under trade name Virazole®.
  • the ribavirin composition used in Virazole® capsules is a non-free flowing powder with low and variable tap densities in the range of 0.320 to 0.449 g/mL, and comprises lactose monohydrate, microcrystalline cellulose, and magnesium stearate as excipients. It is further disclosed that it would be desirable for the ribavirin composition to have a uniformly high tap density of at least 0.6 g/mL to fill any capsule and to avoid excessive weight variation and suggested the dry compaction method to improve the flow.
  • ribavirin formulation technologies some of them are as given below:
  • US patent No. 6,720,000 disclose a process for preparing ribavirin pellets by extrusion and spheronization. However, the pellets prepared by this method are costlier and time consuming.
  • US 2003/0104050 disclose quick dissolving ribavirin composition prepared by a process comprising mixing ribavirin, disintegrant, filler to form an homogenous mixture; granulating the mixture with water; drying the granules; and mixing the dried granules with disintegrant and lubricant.
  • WO 2004/096187 disclose a pharmaceutical composition containing ribavirin as active substance in the mixture with at least one pharmaceutically acceptable excipient characterized in that it is a freely flowing granulate prepared by wet granulation of a mixture of ribavirin, wetted with water, and at least one pharmaceutically acceptable filler selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and optionally at least one pharmaceutically acceptable excipient.
  • EP 1455801 discloses a process for preparing ribavirin granules, comprising preparing granulate solution which involves mixing of a binding agent with an isopropanol/water or ethanol/water-mixture, then stirring the granulate solution into a mixture of ribavirin-powder with sieving and drying the granulates.
  • the main objective of the present invention is to provide composition comprising free flowing ribavirin.
  • Another embodiment of the present invention is to provide simple, cost effective and efficient process for preparing ribavirin composition.
  • Yet another objective of the present invention is to provide ribavirin composition in such a way that it will comply with the reference product in terms of in vitro parameters like dissolution, disintegration, etc and in vivo parameters like bioequivalence.
  • the invention provides a composition comprising free flowing ribavirin and one or more pharmaceutically acceptable excipients, wherein the free flowing ribavirin is prepared by agglomerating the non-free flowing ribavirin using a solvent or by controlling the crystallization during synthesis of ribavirin.
  • the invention also provides a process for preparing ribavirin compositions wherein the composition is prepared by mixing free flowing ribavirin with one or more excipients and finally filling into capsules or compressing into tablets.
  • the present invention describes a composition comprising free flowing ribavirin prepared by a simple process from non free flowing ribavirin without using any excipients or procedures where high pressure is required such as compaction.
  • the free flowing ribavirin is prepared by dissolving ribavirin crude product in a mixture of water and methanol at 65 to 70 0 C. The resulting mixture is treated with charcoal and cooling the filtrate slowly at 50 to 70 0 C, at which temperature the product starts crystallizing resulting into a slurry. Maintaining such slurry at this temperature without agitation for 15-20 min for formation of crystals and stirring for 2.0 hrs and drying the product to obtain free flowing crystals of ribavirin.
  • the free flowing ribavirin is also prepared by adding solvent to non-free flowing ribavirin powder in a mixer, kneading the wet mass, sieving the wet agglomerate, and drying the wet agglomerate at 60 to 80 0 C. The dried granules are shifted through suitable sieves to obtain free flowing ribavirin.
  • the free flowing ribavirin used according to the present invention has bulk density not less than 0.36g/ml and not more than 0.66g/ml, tapped density of not less than 0.4g/ml and not more than 0.8g/ml.
  • the particle size of the free flowing ribavirin used is not more than 600 ⁇ m.
  • the ribavirin prepared by process of the present invention is uniform, free flowing, and have adequate bulk and tapped density for processing into capsules or tablets.
  • the ribavirin compositions are substantially free of polymorphic forms of ribavirin, i.e., there are no signs of change in polymorphic nature of ribavirin.
  • the ribavirin composition of the present invention may be filled into capsules, compressed into conventional or sustained release tablets.
  • the ribavirin composition of the present invention comprises one or more pharmaceutically acceptable excipients selected from fillers, disintegrants, binders, lubricants, glidants, polymers and the like.
  • the sustained release tablets further comprise polymers selected from hydoxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and polyethylene oxide or a combination thereof.
  • the ribavirin composition of present invention complies with the reference product in terms of in vitro parameters like dissolution, disintegration, etc and in vivo parameters like bioequivalence.
  • Suitable solvents used for preparing free flowing ribavirin include water, acetonitrile, acetone, chloroform, methylene chloride, methanol, ethanol, and isopropanol or a combination thereof.
  • Suitable fillers used according to the present invention are selected from lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, dibasic calcium phosphate dihydrate, calcium carbonate, dextrose, sucrose, mannitol, and sorbitol or a combination thereof.
  • Suitable disintegrants used according to the present invention are selected from croscarmellose sodium, sodium starch glycolate, crospovidone, pregelatinized starch, and sodium carboxymethyl cellulose or a combination thereof.
  • Suitable binders of the invention are selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, starch, pregelatinized starch or a combination thereof.
  • Suitable lubricants used according to the present invention are selected from magnesium stearate, calcium stearate, zinc stearate, talc, stearic acid, vegetable oil, and sodium lauryl sulfate or a combination thereof.
  • Suitable glidants used according to the present invention are selected from magnesium trisilicate, talc, and colloidal silicon dioxide or a combination thereof.
  • ribavirin capsules The processing steps involved in manufacturing ribavirin capsules are : i) free flowing ribavirin was loaded in a blender, ii) lactose, microcrystalline cellulose, croscarmellose sodium and povidone were added to free flowing ribavirin and mixed, iii) lubricated the blend obtained from step (ii) with magnesium stearate, and iv) filled the uniform blend into capsules.
  • ribavirin immediate release tablets The processing steps involved in manufacturing ribavirin immediate release tablets are : i) free flowing ribavirin was loaded in a blender, ii) pregelatinized starch, microcrystalline cellulose, croscarmellose sodium and povidone were added to free flowing ribavirin and mixed the blend, iii) lubricated the blend obtained from step (ii) with magnesium stearate, and iv) compressed the blend to obtain tablets.
  • ribavirin sustained release tablets The processing steps involved in manufacturing ribavirin sustained release tablets are: i) free flowing ribavirin was loaded in a blender, ii) pregelatinized starch, microcrystalline cellulose, polymers, and povidone were added to free flowing ribivirin of step (i) and mixed the blend, iii) lubricated the blend obtained from step (ii) with magnesium stearate, and iv) compressed the blend to obtain sustained release tablets.
  • the dissolution studies were performed in 900 ml of water, at 100 RPM by USP I method.
  • the release profile (% of drug released in minutes) is given in table 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An oral pharmaceutical composition comprising free flowing ribavirin and one or more pharmaceutically acceptable excipients, wherein the free flowing ribavirin is prepared by agglomerating the non-free flowing ribavirin using a solvent or by controlling the crystallization during synthesis of ribavirin.

Description

COMPOSITIONS OF ANTIVIRAL COMPOUND
Field of the invention
The present invention relates to composition of an anti-viral compound. More particularly, the present invention relates to compositions comprising free flowing ribavirin.
The present invention also relates to a process for the preparation of compositions comprising free flowing ribavirin.
Background of the invention
Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity and known to be useful in the treatment of hepatitis C as well as various other disease states. Chemically, ribavirin is l-(β)-D-ribofuranosyl-lH-l,2,4- triazole-3-carboxamide and is commercially available in the US as tablets under the trade name of Copegus®; as capsule and oral solution under the trade name of Rebetol® and as inhalation solution under the trade name of Virazole®. Ribavirin is currently indicated for use as a combination therapy with interferon for Hepatitis C. As such, ribavirin is administered in large dosages, e.g., a dose as large as 1200 mg per day, together with interferon injections. Ribavirin is a colorless, water-soluble, stable material and is known to have two polymorphic forms. It is very fluffy, non- free flowing powder, which makes it difficult for filling in capsules or as such compressing into tablets. Even after mixing ribavirin with fillers and lubricants, the composition cannot have sufficient flow and density of blend is not suitable for filling into capsules or compressing into tablets.
US patent Nos. 5,914,128; 5,916,594; 6,051,252; 6,335,032; and 6,337,090 disclose rapidly dissolving compacted ribavirin composition comprising ribavirin and disintegrant and further disclose the composition having a tap density of at least about 0.6 g/mL. Dry compaction utilizes high pressure to form a ribbon of ribavirin that is subsequently reduced to a free flowing powder by milling. The undesirable side effects of manufacturing ribavirin by dry compaction include creation of excessive dust, a potential health hazard, as well as the risk that high pressure, which can produce high heat, may change the polymorphic forms of ribavirin, which are unacceptable for obtaining health registration.
It is disclosed in US 5,914,128 patent that ribavirin is marketed in Canada as capsules under trade name Virazole®. The ribavirin composition used in Virazole® capsules is a non-free flowing powder with low and variable tap densities in the range of 0.320 to 0.449 g/mL, and comprises lactose monohydrate, microcrystalline cellulose, and magnesium stearate as excipients. It is further disclosed that it would be desirable for the ribavirin composition to have a uniformly high tap density of at least 0.6 g/mL to fill any capsule and to avoid excessive weight variation and suggested the dry compaction method to improve the flow. There are few other patents/publications which disclose ribavirin formulation technologies, some of them are as given below:
US patent No. 6,720,000 disclose a process for preparing ribavirin pellets by extrusion and spheronization. However, the pellets prepared by this method are costlier and time consuming. US 2003/0104050 disclose quick dissolving ribavirin composition prepared by a process comprising mixing ribavirin, disintegrant, filler to form an homogenous mixture; granulating the mixture with water; drying the granules; and mixing the dried granules with disintegrant and lubricant.
WO 2004/096187 disclose a pharmaceutical composition containing ribavirin as active substance in the mixture with at least one pharmaceutically acceptable excipient characterized in that it is a freely flowing granulate prepared by wet granulation of a mixture of ribavirin, wetted with water, and at least one pharmaceutically acceptable filler selected from the group including cellulose and its derivatives and carbonates, phosphates, sulfates and silicates of metals, and optionally at least one pharmaceutically acceptable excipient.
EP 1455801 discloses a process for preparing ribavirin granules, comprising preparing granulate solution which involves mixing of a binding agent with an isopropanol/water or ethanol/water-mixture, then stirring the granulate solution into a mixture of ribavirin-powder with sieving and drying the granulates.
The above prior art references discloses various technologies for preparing ribavirin composition. However, still there is a need for making ribavirin composition, which involves simple process and does not involve high pressure compaction process and costlier pelletization technique. The inventors of the present invention during their continuous effort to develop ribavirin compositions, found that blending of free flowing ribavirin with other excipients produces composition which have uniform dissolution profile and does not cause the formation of undesired ribavirin polymorphic forms.
Objective of the invention
Accordingly, the main objective of the present invention is to provide composition comprising free flowing ribavirin.
Yet, another embodiment of the present invention is to provide simple, cost effective and efficient process for preparing ribavirin composition.
Yet another objective of the present invention is to provide ribavirin composition in such a way that it will comply with the reference product in terms of in vitro parameters like dissolution, disintegration, etc and in vivo parameters like bioequivalence. Summary of the Invention
Accordingly, to the main embodiment, the invention provides a composition comprising free flowing ribavirin and one or more pharmaceutically acceptable excipients, wherein the free flowing ribavirin is prepared by agglomerating the non-free flowing ribavirin using a solvent or by controlling the crystallization during synthesis of ribavirin.
The invention also provides a process for preparing ribavirin compositions wherein the composition is prepared by mixing free flowing ribavirin with one or more excipients and finally filling into capsules or compressing into tablets.
Detailed description of the invention
The present invention describes a composition comprising free flowing ribavirin prepared by a simple process from non free flowing ribavirin without using any excipients or procedures where high pressure is required such as compaction.
The free flowing ribavirin is prepared by dissolving ribavirin crude product in a mixture of water and methanol at 65 to 70 0C. The resulting mixture is treated with charcoal and cooling the filtrate slowly at 50 to 70 0C, at which temperature the product starts crystallizing resulting into a slurry. Maintaining such slurry at this temperature without agitation for 15-20 min for formation of crystals and stirring for 2.0 hrs and drying the product to obtain free flowing crystals of ribavirin. The free flowing ribavirin is also prepared by adding solvent to non-free flowing ribavirin powder in a mixer, kneading the wet mass, sieving the wet agglomerate, and drying the wet agglomerate at 60 to 80 0C. The dried granules are shifted through suitable sieves to obtain free flowing ribavirin.
In an embodiment of the present invention, the free flowing ribavirin used according to the present invention has bulk density not less than 0.36g/ml and not more than 0.66g/ml, tapped density of not less than 0.4g/ml and not more than 0.8g/ml.
In yet another embodiment of the present invention, the particle size of the free flowing ribavirin used is not more than 600 μm. The ribavirin prepared by process of the present invention is uniform, free flowing, and have adequate bulk and tapped density for processing into capsules or tablets. Furthermore, the ribavirin compositions are substantially free of polymorphic forms of ribavirin, i.e., there are no signs of change in polymorphic nature of ribavirin.
In an embodiment, the ribavirin composition of the present invention may be filled into capsules, compressed into conventional or sustained release tablets.
In an embodiment, the ribavirin composition of the present invention comprises one or more pharmaceutically acceptable excipients selected from fillers, disintegrants, binders, lubricants, glidants, polymers and the like.
The sustained release tablets further comprise polymers selected from hydoxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and polyethylene oxide or a combination thereof.
The ribavirin composition of present invention complies with the reference product in terms of in vitro parameters like dissolution, disintegration, etc and in vivo parameters like bioequivalence.
Suitable solvents used for preparing free flowing ribavirin include water, acetonitrile, acetone, chloroform, methylene chloride, methanol, ethanol, and isopropanol or a combination thereof. Suitable fillers used according to the present invention are selected from lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, dibasic calcium phosphate dihydrate, calcium carbonate, dextrose, sucrose, mannitol, and sorbitol or a combination thereof.
Suitable disintegrants used according to the present invention are selected from croscarmellose sodium, sodium starch glycolate, crospovidone, pregelatinized starch, and sodium carboxymethyl cellulose or a combination thereof. Suitable binders of the invention are selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, starch, pregelatinized starch or a combination thereof.
Suitable lubricants used according to the present invention are selected from magnesium stearate, calcium stearate, zinc stearate, talc, stearic acid, vegetable oil, and sodium lauryl sulfate or a combination thereof.
Suitable glidants used according to the present invention are selected from magnesium trisilicate, talc, and colloidal silicon dioxide or a combination thereof.
The following examples further exemplify the invention and are not intended to limit the scope of the invention. It is obvious to those skilled in the art to find out the composition for other dosage forms and substitute the equivalent excipients as described in this specification or with the one known to the industry.
Example 1
Ribavirin capsules
The processing steps involved in manufacturing ribavirin capsules are : i) free flowing ribavirin was loaded in a blender, ii) lactose, microcrystalline cellulose, croscarmellose sodium and povidone were added to free flowing ribavirin and mixed, iii) lubricated the blend obtained from step (ii) with magnesium stearate, and iv) filled the uniform blend into capsules.
The capsules disclosed in the following examples are prepared by similar process described in example 1.
Example 2
Ribavirin capsules
Example 3
Ribavirin capsules
Example 4
Immediate release ribavirin tablets
S. No. Ingredient Qty/capsule
1 Free flowing Ribavirin 200 mg
Pregelatinized starch 20 to 50 mg
Microcrystalline cellulose 50 to 100 mg
Sodium starch glycolate 6 to 30 mg
The processing steps involved in manufacturing ribavirin immediate release tablets are : i) free flowing ribavirin was loaded in a blender, ii) pregelatinized starch, microcrystalline cellulose, croscarmellose sodium and povidone were added to free flowing ribavirin and mixed the blend, iii) lubricated the blend obtained from step (ii) with magnesium stearate, and iv) compressed the blend to obtain tablets.
The immediate release tablets disclosed in the following examples are prepared by similar process described in example 4.
Example 5
Immediate release ribavirin tablets
Example 6
Immediate release ribavirin tablets
Example 7
Sustained release Ribavirin tablets
The processing steps involved in manufacturing ribavirin sustained release tablets are: i) free flowing ribavirin was loaded in a blender, ii) pregelatinized starch, microcrystalline cellulose, polymers, and povidone were added to free flowing ribivirin of step (i) and mixed the blend, iii) lubricated the blend obtained from step (ii) with magnesium stearate, and iv) compressed the blend to obtain sustained release tablets.
Dissolution profile :
The dissolution studies were performed in 900 ml of water, at 100 RPM by USP I method. The release profile (% of drug released in minutes) is given in table 1.
Table I

Claims

We claim :
1. A composition comprising free flowing ribavirin and one or more pharmaceutically acceptable excipients, wherein the free flowing ribavirin is prepared by agglomerating the non-free flowing ribavirin using a solvent or by controlling the crystallization during synthesis of ribavirin.
2. The free flowing ribavirin as claimed in claim 1," prepared by crystallization process.
3. The crystallization process as claimed in claim 2, comprises the steps of dissolving ribavirin crude product in a mixture of water and methanol at 65 to 70 0C, treating the resulting mixture with charcoal, cooling the filtrate slowly at 50 to 70 0C to form a slurry, maintaining the slurry at this temperature without agitation for 15-20 min to form crystals, stirring for 2.0 hrs and drying the crystals.
4. The free flowing ribavirin as claimed in claim I5 prepared by agglomeration process.
5. The agglomeration process as claimed in claim 4, comprises the steps of adding solvent to non free flowing ribavirin powder in a mixer, kneading the wet mass, sieving the wet agglomerate, drying at 60 to 80 0C and sifting the dried the granules through sieves.
6. The process as claimed in claim 3, wherein the solvent used is selected from water, acetonitrile, acetone, chloroform, methylene chloride, methanol, ethanol, isopropanol or a combination thereof.
7. The free flowing ribavirin as claimed in claim 1, having bulk density not less than 0.36g/ml and not more than 0.66g/ml, tapped density of not less than 0.4g/ml and not more than 0.8g/ml and
8. The free flowing ribavirin as claimed in claim 1, has a particle size of less than 600 μm.
9. The composition as claimed in claim 1, wherein pharmaceutically acceptable excipient is selected from fillers, disintegrants, binders, glidants and lubricants.
10. The composition as claimed in claim 9, wherein filler is selected from lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, dibasic calcium phosphate dihydrate, calcium carbonate, dextrose, sucrose, mannitol, sorbitol or a combination thereof.
11. The composition as claimed in claim 9, wherein disintegrant is selected from croscarmellose sodium, sodium starch glycolate, crospovidone, pregelatinized starch, sodium carboxymethyl cellulose or a combination thereof.
12. The composition as claimed in claim 9, wherein lubricant is selected from magnesium stearate, calcium stearate, zinc stearate, talc, stearic acid, vegetable oil, sodium lauryl sulfate or a combination thereof.
13. The composition as claimed in claim 1, is in the form of capsules, immediate release tablets or sustained release tablets.
EP06765637A 2005-07-08 2006-07-05 Compositions of antiviral compound Withdrawn EP1904071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN906CH2005 2005-07-08
PCT/IB2006/001952 WO2007007183A2 (en) 2005-07-08 2006-07-05 Compositions of antiviral compound

Publications (1)

Publication Number Publication Date
EP1904071A2 true EP1904071A2 (en) 2008-04-02

Family

ID=37564409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06765637A Withdrawn EP1904071A2 (en) 2005-07-08 2006-07-05 Compositions of antiviral compound

Country Status (2)

Country Link
EP (1) EP1904071A2 (en)
WO (1) WO2007007183A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60101056T2 (en) * 2001-07-30 2004-05-19 Clariant Life Science Molecules (Italia) S.P.A., Origgio Process for the preparation of ribavirin
US20050123612A1 (en) * 2001-12-21 2005-06-09 Cornelis Sobel Ribavirin granulate for producing coated tablets
WO2004026261A2 (en) * 2002-09-19 2004-04-01 Three Rivers Pharmaceuticals, Llc Composition containing ribavirin and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007007183A3 *

Also Published As

Publication number Publication date
WO2007007183A3 (en) 2007-08-23
WO2007007183A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
JP6560289B2 (en) New pharmaceutical composition
US6511681B2 (en) Aqueous solubility pharmaceutical formulations
JP6574477B2 (en) Lucaparib high dose tablet
AU2009236289B2 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS
KR101613775B1 (en) Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof
JP4875001B2 (en) Wet granulation pharmaceutical composition of aripiprazole
JP6895779B2 (en) Azilsartan-containing solid pharmaceutical composition
AU2004238038A1 (en) Bicalutamide forms, compositions, and processes thereof
WO2008149338A2 (en) Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
KR20230107902A (en) Tablet formulation for cgrp-active compounds
EP2203156A2 (en) Candesartan cilexetil
US6365196B1 (en) Controlled release solid dosage forms of lithium carbonate
JP3397385B2 (en) Disintegration delay prevention tablets
WO2019012552A4 (en) Compositions of ferric organic compounds
EP2946771B1 (en) Water-dispersible tablet formulation comprising deferasirox
WO2007007183A2 (en) Compositions of antiviral compound
CA3098208A1 (en) Tablet compositions comprising abiraterone acetate
JP3896002B2 (en) tablet
WO2024030098A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
WO2019008426A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
EP4321154A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
WO2023158411A1 (en) A tablet of tolvaptan and at least one binder processed with wet granulation
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib
JP2993321B2 (en) Anticancer composition for oral administration
RU2289422C2 (en) "noopept"-base pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090812

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140201